Anti-Mullerian hormone and female reproduction. |
Jung Ryeol Lee, Seok Hyun Kim |
1Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea. seokhyun@snu.ac.kr 2Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seoul, Korea. 3Institute of Reproductive Medicine and Population, Medical Research Center,Seoul National University, Seoul, Korea. |
|
Abstract |
Anti-Mullerian hormone (AMH), also called Mullerian-inhibiting substance, is a member of the transforming growth factor (TGF)-beta superfamily. It is well known that AMH is expressed by Sertoli cells in fetal testis, and that it induces Mullerian duct degeneration during male fetal development. However, in females AMH is produced by granulosa cells of the ovarian follicles. Recently, numerous studies have demonstrated that AMH could be a useful marker of ovarian function. Serum AMH levels decrease progressively with age, become undetectable after menopause, and show high cycle-to-cycle reproducibility. It has been shown that AMH level is correlated with various outcomes of controlled ovarian hyperstimulation (COH). Many studies showed that AMH can discriminate very effectively poor responders, cycle cancellation, and ovarian hyperstimulation syndrome after COH. AMH also has a functional role in folliculogenesis and could be a qualitative marker of ovarian follicular states. In addition, AMH has been associated with various clinical statuses such as polycystic ovarian syndrome, endometriosis, obesity, granulosa cell tumor, and premature ovarian failure. AMH is an effective and promising biomarker of various conditions in female reproduction. In this article, current research results on role of AMH as a marker of ovarian function and dysfunction are discussed. |
Key Words:
Anti-Mullerian hormone, Ovarian reserve, Controlled ovarian hyperstimulation, Outcome predictor, Folliculogenesis |
|